CO2022010547A2 - Compuestos y usos de los mismos - Google Patents

Compuestos y usos de los mismos

Info

Publication number
CO2022010547A2
CO2022010547A2 CONC2022/0010547A CO2022010547A CO2022010547A2 CO 2022010547 A2 CO2022010547 A2 CO 2022010547A2 CO 2022010547 A CO2022010547 A CO 2022010547A CO 2022010547 A2 CO2022010547 A2 CO 2022010547A2
Authority
CO
Colombia
Prior art keywords
compounds
treatment
present description
compounds useful
disorders related
Prior art date
Application number
CONC2022/0010547A
Other languages
English (en)
Inventor
Rishi G Vaswani
David S Huang
Original Assignee
Foghorn Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foghorn Therapeutics Inc filed Critical Foghorn Therapeutics Inc
Publication of CO2022010547A2 publication Critical patent/CO2022010547A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente descripción presenta compuestos útiles para el tratamiento de trastornos relacionados con el complejo BAF.
CONC2022/0010547A 2020-01-29 2022-07-27 Compuestos y usos de los mismos CO2022010547A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062967359P 2020-01-29 2020-01-29
PCT/US2021/015876 WO2021155262A1 (en) 2020-01-29 2021-01-29 Compounds and uses thereof

Publications (1)

Publication Number Publication Date
CO2022010547A2 true CO2022010547A2 (es) 2022-09-09

Family

ID=76970694

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0010547A CO2022010547A2 (es) 2020-01-29 2022-07-27 Compuestos y usos de los mismos

Country Status (15)

Country Link
US (3) US11485732B2 (es)
EP (1) EP4096664A4 (es)
JP (1) JP2023512039A (es)
KR (1) KR20220133258A (es)
CN (1) CN115023226A (es)
AR (1) AR121226A1 (es)
AU (1) AU2021213811A1 (es)
BR (1) BR112022015004A2 (es)
CA (1) CA3167275A1 (es)
CO (1) CO2022010547A2 (es)
IL (1) IL295100A (es)
MX (1) MX2022009309A (es)
TW (1) TW202136252A (es)
WO (1) WO2021155262A1 (es)
ZA (1) ZA202207804B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND USES THEREOF
EP4153176A4 (en) * 2020-05-20 2024-05-29 Foghorn Therapeutics Inc METHODS OF TREATING CANCER
US20240158387A1 (en) * 2021-03-09 2024-05-16 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
CN117337179A (zh) * 2021-03-19 2024-01-02 福宏治疗公司 Brg1和brm的酶活性抑制剂的治疗方案
WO2023009834A2 (en) * 2021-07-29 2023-02-02 Foghorn Therapeutics Inc. Methods of treating cancer
WO2023196565A1 (en) * 2022-04-08 2023-10-12 Foghorn Therapeutics, Inc. Methods of treating cancer
WO2023196560A1 (en) * 2022-04-08 2023-10-12 Foghorn Therapeutics Inc. Methods of treating cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2788341A (en) 1953-03-06 1957-04-09 Ciba Pharm Prod Inc Process for the manufacture of aminoacyl compounds
US3624097A (en) 1969-07-22 1971-11-30 Warner Lambert Co N-pyridine 5-aminooxazoles
US20050079512A1 (en) 2003-02-26 2005-04-14 Emerson Beverly M. Methods of modulating gene expression
EP2148678A4 (en) 2007-05-23 2010-08-04 Siga Technologies Inc ANTIVIRAL DRUGS FOR THE TREATMENT AND PREVENTION OF DENGUE INFECTION
BR112012023355A2 (pt) 2010-03-17 2016-05-31 Taivex Therapeutics Inc composto, composição farmacêutica e método de ruptura da interação nek2/hec1
US9410943B2 (en) 2013-03-14 2016-08-09 The Board Of Trustees Of The Leland Stanford Junior University Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
EP2968318A4 (en) 2013-03-15 2016-12-14 Shifa Biomedical Corp ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES
WO2014150751A2 (en) 2013-03-15 2014-09-25 Novartis Ag Biomarkers associated with brm inhibition
US10976320B2 (en) 2013-05-21 2021-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods for identifying and treating cancer patients
JPWO2015005473A1 (ja) 2013-07-12 2017-03-02 国立研究開発法人国立がん研究センター がんの治療への応答性を予測する方法
WO2015046193A1 (ja) 2013-09-25 2015-04-02 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
EP3102193B1 (en) 2014-02-06 2023-01-11 Rutgers, The State University of New Jersey Antibacterial agents: n(alpha)-aroyl-n-aryl-phenylalaninamides
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
US20180328913A1 (en) 2015-11-19 2018-11-15 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
JP6315150B2 (ja) 2016-02-29 2018-04-25 フジテック株式会社 情報提供装置、エレベータの群管理システム、及びエレベータシステム
KR20190140438A (ko) 2017-02-28 2019-12-19 에피자임, 인코포레이티드 암 치료를 위한 smarca2의 저해
WO2019040098A1 (en) 2017-08-21 2019-02-28 Dana-Farber Cancer Institute, Inc. METHODS OF MODULATING THE INTERACTION BETWEEN BAF COMPLEXES AND EWS-FLI1
EP3746124A4 (en) * 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND USES THEREOF
EP3801494A4 (en) 2018-05-25 2022-05-11 Rutgers, The State University of New Jersey ANTIBACTERIAL AGENTS: DUAL TARGETING RNA POLYMERASE INHIBITORS
EP3837256B1 (en) 2018-08-17 2023-03-08 Novartis AG Urea compounds and compositions as smarca2/brm-atpase inhibitors
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
US20210388040A1 (en) 2018-10-17 2021-12-16 Dana-Farber Cancer Institute, Inc. Non-canonical swi/snf complex and uses thereof
EP3883580A4 (en) 2018-11-21 2023-01-04 Foghorn Therapeutics Inc. METHODS OF TREATMENT OF CANCER
US20220119378A1 (en) 2019-01-29 2022-04-21 Foghorn Therapeutics Inc. Compounds and uses thereof
AU2020214308A1 (en) * 2019-01-29 2021-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021081032A1 (en) 2019-10-25 2021-04-29 Dana-Farber Cancer Institute, Inc. Compositions comprising modified smarcb1 and uses thereof
EP4096668A4 (en) 2020-01-29 2024-02-28 Foghorn Therapeutics Inc COMPOUNDS AND THEIR USES
WO2021183218A1 (en) 2020-03-13 2021-09-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes

Also Published As

Publication number Publication date
US20210230154A1 (en) 2021-07-29
EP4096664A1 (en) 2022-12-07
AU2021213811A1 (en) 2022-07-28
MX2022009309A (es) 2022-08-22
TW202136252A (zh) 2021-10-01
KR20220133258A (ko) 2022-10-04
IL295100A (en) 2022-09-01
US20230129003A1 (en) 2023-04-27
BR112022015004A2 (pt) 2022-09-20
CA3167275A1 (en) 2021-08-05
WO2021155262A1 (en) 2021-08-05
US20240101550A1 (en) 2024-03-28
EP4096664A4 (en) 2024-02-28
US11485732B2 (en) 2022-11-01
ZA202207804B (en) 2023-12-20
AR121226A1 (es) 2022-04-27
JP2023512039A (ja) 2023-03-23
CN115023226A (zh) 2022-09-06

Similar Documents

Publication Publication Date Title
CO2022010547A2 (es) Compuestos y usos de los mismos
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
ECSP20040257A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
CL2017001124A1 (es) Agentes inmunomoduladores
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
ECSP16071151A (es) Inhibidores de dihidropirrolopiridina de ror-gamma
UY36371A (es) Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
SV2016005330A (es) Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cã�ncer
ECSP21016032A (es) Inhibidores de la interacción proteína-proteína keap1-nrf2
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
ECSP19066721A (es) Inhibidores duales de magl y faah
ECSP23076906A (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2023002223A1 (es) Inhibidores de cdk2 y métodos de uso de los mismos
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
CL2022002531A1 (es) Moduladores de nlrp3